Older Americans are quitting GLP-1 weight-loss drugs for 4 key reasons

A JAMA study of >125,000 overweight or obese patients found high discontinuation of GLP-1 therapies within a year (≈47% with type 2 diabetes, 65% without), with older adults particularly affected given ~40% obesity prevalence. Key drivers of non-adherence are cost and coverage losses (examples of copays jumping from $25 to >$1,000/month), tolerability (GI side effects, dehydration) and clinically meaningful muscle loss in seniors, which can negate cardiometabolic benefits and raise safety concerns. These trends imply downside risk to GLP-1 revenue durability and uptake forecasts, heightened payer and access scrutiny, and potential need for manufacturers to adjust pricing, delivery and patient-management strategies (e.g., Lilly’s announced price cut for tirzepatide vials).

Analysis

Market structure: Large-cap GLP-1 originators (NVO, LLY) retain pricing power but face a lower-than-advertised effective market because real-world adherence is weak — JAMA: ~47% (T2D) and ~65% (non‑T2D) stop within a year — which compresses lifetime revenue per patient by an order of magnitude versus chronic-use models. Payer formulary actions and out‑of‑pocket shocks will shift share toward lower‑priced competitors, compounding pharmacies and off‑label cash markets, while insurers/PBMs can extract margin by restricting coverage.

Risk assessment: Key tails are (1) class safety/regulatory action (label warnings on muscle loss/dehydration) triggering 20–40% demand shock, (2) broad payer coverage removals (Medicare/MA or 10 largest PBMs) within 30–90 days, and (3) supply shortages driving short‑term price spikes but long‑term access erosion. Immediate volatility will cluster around payer announcements and quarterly prints (next 30–90 days); structural impacts play out over 6–24 months as adherence and chronicity data accumulate.

Trade implications: Favor defensive, option‑structured long exposure to NVO/LLY to capture continued secular demand while capping downside (6–12 month call spreads ATM vs 10–15% OTM). Short lower‑quality consumer/clinic names (WW, small specialist chains) that rely on first‑time, cash customers who churn quickly. Hedge portfolio tail risk with low‑cost put spreads keyed to regulatory/payer headlines in the 3‑month window.

Key Decisions for Investors

• Establish a 2–3% portfolio long in NVO via a 6–12 month call spread (buy ATM call, sell 10–15% OTM call) to capture durable GLP‑1 demand while limiting downside; add up to +1.5% if sequential global GLP‑1 volume growth >12% q/q or net price/mix declines <5% on next quarterly report.
• Initiate a 1.5–2% long position in LLY (stock or 9‑month LEAP call) to play Zepbound access moves and device/price initiatives; liquidate if company announces an incremental price cut >10% or reports net new patient additions <5% q/q for two consecutive quarters.
• Implement a pair trade: long NVO (2%) / short WW (WW) (1.5%) to capture relative resilience of large pharma versus cash‑dependent consumer weight‑loss operators; unwind if the pair diverges by <3% over a 3‑month window or if WW reports improving multi‑month retention >10%.
• Buy 3‑month put spreads (cost‑limited hedge) equal to 0.5–1% portfolio notional keyed to regulatory/payer risk (targeting out‑of‑the‑money strikes ~10% below current) to protect against a sudden class‑wide safety or coverage removal; monitor CMS/PBM formulary decisions and reduce NVO/LLY exposure by 50% within 48 hours if a top‑5 payer delists GLP‑1s for obesity.